Oxaliplatin-eluting microspheres for the treatment of intrahepatic cholangiocarcinoma: A case report

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 2987-2990

  Poggi, Guido ^a,d   Quaretti, Pietro ^c   Minoia, Claudio ^b   Palumbo, Ilaria ^a   Villani, Laura ^a   Amatu, Alessio ^a   Teragni, Cristina ^a   Scelsi, Mario ^a   Zappoli, Federico ^c   Bernardo, Giovanni ^a  

^a Department of Oncology ^*

^b IRCCS   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UO Oncologia II   (Italy)

Author keywords

Intrahepatic cholangiocarcinoma; Microspheres; Oxaliplatin; TACE

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IODIXANOL; MICROSPHERE; OXALIPLATIN;

AGED; ANAMNESIS; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CASE REPORT; CHEMOEMBOLIZATION; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN TISSUE; INTRAHEPATIC BILE DUCT; LABORATORY TEST; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHEMOEMBOLIZATION, THERAPEUTIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MICROSPHERES; ORGANOPLATINUM COMPOUNDS;

EID: 55749116354     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ferrari VD, Amoroso V, Valcamonico F, Fusi A, Simoncini E, Vasalli L, Rangoni G, Mambrini A, Marpicati P, Montini E and Marini G: Epirubicin, cisplatin, and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma: a phase II study. Am J Clin Oncol 27: 445-448, 2004.
2. Poggi G, Quaretti P, Minoia C, Massa Saluzzo C, Riccardi A, Gaggeri R, Teragni C, Delmonte A, Amatu A, Ronchi A, Sottani C, Saini G, Bernieri S and Bernardo G: Transarterial hepatic chemoembolization (TACE) with oxaliplatin-loaded microspheres (HepaSphere) and percutaneous radiofrequency thermal ablation (RFA) as a combined therapy for unresectable hepatic tumors. World Conference on Interventional Oncology (WCIO) 2007, abs, p27 (http://www.wcio2012.com/2007/Abstracts/WCIO-P27a.cgi).
3. Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet 366: 1303-1314, 2005.
4. Yachimski P and Pratt DS: Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 42: 178-190, 2008.
5. Burger I, Hong K, Schulick R, Georgiades C, Thuluvath P, Choti M, Kamel I and Geschwind JF: Transcatheter arterial chemoembolization in unresectable Cholangiocarcinoma: initial experience in a single institution. J Vase Interv Radiol 16: 353-361, 2005.
6. Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque AM, Frome AI, Lahoti S, Ellis L, Vauthey JN, Curley SA, Schnirer II and Raijman I: Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 7: 3375-3380, 2001.
7. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim JS and Kim YH: Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 23: 425-428, 2000.
8. Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J and Armand JP: Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9: 653-656, 1998.
9. Ellis PA, Norman A, Hill A, O'Brien ME, Nicolson M, Hickish T and Cunningham D: Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 31: 1594-1598, 1995.
10. Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M and Forschen R: Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 87: 702-704, 2002.
11. Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, Mauceri G, Caruso M, Tirrito ML and Valdesi M: Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 19: 4089-4091, 2001.
12. Papakostas P, Kouroussis C, Androulakis N, Samelis G, Aravantinos G, Kalbakis K, Sarra E, Souglakos J, Kakolyris S and Georgoulias V: First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 37: 1833-1838, 2001.
13. Thongprasert S, Napapan S, Charoentum C and Moonprakan S: Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma Ann Oncol 16: 279-281, 2005.
14. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J and Bruix J; Barcelona Liver Cancer Group: Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739, 2002.
15. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST and Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for hepatocellular carcinoma: is there room for a new studies? Clin Gastroenterol 32: 383-389, 2001.
16. Tanaka N, Yamakado K, Nakatsuka A, Fujii A, Matsumura K and Takeda K: Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma-initial experience. Eur J Radiol 41: 42-48, 2002.